Yahoo
NasdaqGS - Nasdaq Real Time Price USD

QuidelOrtho Corporation (QDEL)

13.25 -0.51 (-3.71%)
At close: 4:00:00 PM EDT
13.25 0.00 (0.00%)
After hours: 7:08:03 PM EDT
Trade QDEL on Coinbase
Chart Range Bar
Loading chart for QDEL
  • Previous Close 13.76
  • Open 13.46
  • Bid 9.60 x 200
  • Ask 16.14 x 200
  • Day's Range 12.48 - 13.51
  • 52 Week Range 9.92 - 35.58
  • Volume 1,737,172
  • Avg. Volume 1,774,739
  • Market Cap (intraday) 908.624M
  • Beta (5Y Monthly) 0.78
  • PE Ratio (TTM) --
  • EPS (TTM) -15.39
  • Earnings Date Nov 3, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 14.67
  • Motley Fool Rating Bearish

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

www.quidelortho.com

6,500

Full Time Employees

December 28

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

QDEL
53.61%
S&P 500 (^GSPC)
10.73%

1-Year Return

QDEL
50.58%
S&P 500 (^GSPC)
11.11%

3-Year Return

QDEL
77.97%
S&P 500 (^GSPC)
81.91%

5-Year Return

QDEL
90.02%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 630.9M
Earnings -92.9M
Profit Margin -14.72%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-500M
0
500M
-100.0%
-80.0%
-60.0%
-40.0%
-20.0%

Analyst Insights

View More

Analyst Price Targets

12.00 Low
14.67 Average
13.25 Current
20.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 7/8/2026
Analyst Citigroup
Rating Action Maintains
Rating Neutral
Price Action Raises
Price Target 13 -> 18

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -39.20%

  • Return on Assets (ttm)

    0.38%

  • Return on Equity (ttm)

    -45.91%

  • Revenue (ttm)

    2.67B

  • Net Income Avi to Common (ttm)

    -1.05B

  • Diluted EPS (ttm)

    -15.39

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    123.4M

  • Total Debt/Equity (mrq)

    173.28%

  • Levered Free Cash Flow (ttm)

    146.76M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: